Disease progression in patients with single, large-scale mitochondrial DNA deletions

Brain

Volumn 137, Issue 2, 2014, Pages 323-334

  Grady, John P ^a   Campbell, Georgia ^a   Ratnaike, Thiloka ^a   Blakely, Emma L ^a   Falkous, Gavin ^a   Nesbitt, Victoria ^a   Schaefer, Andrew M ^a   Mcnally, Richard J ^a   Gorman, Grainne S ^a   Taylor, Robert W ^a   Turnbull, Doug M ^a   Mcfarland, Robert ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

disease progression; mitochondrial diseases; mitochondrial DNA deletion

Indexed keywords

MITOCHONDRIAL DNA;

ARTICLE; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; COHORT ANALYSIS; DISEASE COURSE; GENE DELETION; GENOME; HETEROPLASMY; HUMAN; KEARNS SAYRE SYNDROME; MAJOR CLINICAL STUDY; MITOCHONDRIAL DNA DISORDER; MYOPATHY; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; SKELETAL MUSCLE;

DISEASE PROGRESSION; MITOCHONDRIAL DISEASES; MITOCHONDRIAL DNA DELETION;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; DNA, MITOCHONDRIAL; FEMALE; GENE DELETION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MITOCHONDRIAL DISEASES;

EID: 84893856024     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt321     Document Type: Article

References (58)

1. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; AC-19: 716-23
2. Apabhai S, Gorman GS, Sutton L, Elson JL, Plötz T, Turnbull DM, et al. Habitual physical activity in mitochondrial disease. PLoS One 2011; 6: E22294
3. AuréK, Ogier de Baulny H, Laforêt P, Jardel C, Eymard B, Lombès A. Chronic progressive ophthalmoplegia with large-scale mtDNA rearrangement: Can we predict progression? Brain 2007; 130: 1516-24
4. Bates MG, Hollingsworth KG, Newman JH, Jakovljevic DG, Blamire AM, MacGowan GA, et al. Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers. Eur Heart J Cardiovasc Imaging 2013; 14: 650-8
5. Blackwood JK, Whittaker RG, Blakely EL, Alston CL, Turnbull DM, Taylor RW. The investigation and diagnosis of pathogenic mitochondrial DNA mutations in human urothelial cells. Biochem Biophys Res Commun 2010; 393: 740-5
6. Box GEP, Cox DR. An analysis of transformations. J R Stat Soc B 1964; 26: 211-52
7. De Laat P, Koene S, van Den Heuvel LP, Rodenburg RJ, Janssen MC, Smeitink JA. Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A4G mutation. J Inherit Metab Dis 2012; 35: 1059-69
8. den Heijer T, van Der Lijn F, Koudstaal PJ, Hofman A, van Der Lugt A, Krestin GP, et al. A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 2010; 133: 1163-72
9. Diggle PJ, Heagerty P, Liang KY, Zeger SL. Analysis of longitudinal data. Second edn. Oxford: Oxford University Press; 2002
10. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, et al. Cognitive-behavioral therapy for depression in Parkinson?s disease: A randomized, controlled trial. Am J Psychiatry 2011; 168: 1066-74
11. Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008; 83: 254-60
12. Enns GM, Kinsman SL, Perlman SL, Spicer KM, Abdenur JE, Cohen BH, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 2012; 105: 91-102
13. Galvin JE, Powlishta KK, Wilkins K, McKeel DW Jr, Xiong C, Grant E, et al. Predictors of preclinical alzheimer disease and dementia: A clinicopathologic study. Arch Neurol 2005; 62: 758-65
14. Gellerich FN, Deschauer M, Chen Y, Müller T, Neudecker S, Zierz S. Mitochondrial respiratory rates and activities of respiratory chain complexes correlate linearly with heteroplasmy of deleted mtDNA without threshold and independently of deletion size. Biochim Biophys Acta 2002; 1556: 41-52
15. Goto Y, Koga Y, Horai S, Nonaka I. Chronic progressive external ophthalmoplegia: A correlative study of mitochondrial DNA deletions and their phenotypic expression in muscle biopsies. J Neurol Sci 1990; 100: 63-9
16. Hassing LB, Grant MD, Hofer SM, Pedersen NL, Nilsson SE, Berg S, et al. Type 2 diabetes mellitus contributes to cognitive decline in old age: A longitudinal population-based study. J Int Neuropsychol Soc 2004; 10: 599-607
17. He L, Chinnery PF, Durham SE, Blakely EL, Wardell TM, Borthwick GM, et al. Detection and quantification of mitochondrial DNA deletions in individual cells by real-Time PCR. Nucleic Acids Res 2002; 30: E68
18. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988; 331: 717-19
19. Holt IJ, Harding AE, Cooper JM, Schapira AH, Toscano A, Clark JB, et al. Mitochondrial myopathies: Clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Ann Neurol 1989; 26: 699-708
20. Ishikawa Y, Goto YI, Minami R. Progression in a case of Kearns-Sayre syndrome. J Child Neurol 2000; 15: 750-5
21. Jacobs LJ, Jongbloed RJ, Wijburg FA, de Klerk JB, Geraedts JP, Nijland JG, et al. Pearson syndrome and the role of deletion dimers and duplications in the mtDNA. J Inherit Metab Dis 2004; 27: 47-55
22. Johns DR, Rutledge SL, Stine OC, Hurko O. Directly repeated sequences associated with pathogenic mitochondrial DNA deletions. Proc Natl Acad Sci USA 1989; 86: 8059-62
23. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009; 66: 1254-9
24. Johnson DK, Galvin JE. Longitudinal changes in cognition in Parkinson?s disease with and without dementia. Dement Geriatr Cogn Disord 2011; 31: 98-108
25. Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia and complete heart block. Arch Ophthalmol 1958; 60: 280-289
26. Khrapko K, Bodyak N, Thilly WG, van Orsouw NJ, Zhang X, Coller HA, et al. Cell-by-cell scanning of whole mitochondrial genomes in aged human heart reveals a significant fraction of myocytes with clonally expanded deletions. Nucleic Acids Res 1999; 27: 2434-41
27. Knopman DS, Mosley TH, Catellier DJ, Coker LH. Atherosclerosis Risk in Communities Study Brain MRI Study. Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study. Alzheimer?s Dement 2009; 5: 207-14
28. Kornblum C, Nicholls TJ, Haack TB, Schöler S, Peeva V, Danhauser K, et al. Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease. Nat Genet 2013; 45: 214-19
29. Krishnan KJ, Bender A, Taylor RW, Turnbull DM. A multiplex real-Time PCR method to detect and quantify mitochondrial DNA deletions in individual cells. Anal Biochem 2007; 370: 127-9
30. Kuha J. AIC and BIC. Sociol Methods Res 2004; 33: 188-229
31. Larsson NG, Holme E. Multiple short direct repeats associated with single mtDNA deletions. Biochim Biophys Acta 1992; 1139: 311-4
32. Lax NZ, Hepplewhite PD, Reeve AK, Nesbitt V, McFarland R, Jaros E, et al. Cerebellar ataxia in patients with mitochondrial DNA disease: A molecular clinicopathological study. J Neuropathol Exp Neurol 2012; 71: 148-61
33. López-Gallardo E, López-Pérez MJ, Montoya J, Ruiz-Pesini E. Cpeo and kss differ in the percentage and location of the mtdna deletion Mitochondrion 2009 9 314-17
34. Mancuso M, Orsucci D, Ienco EC, Pini E, Choub A, Siciliano G. Psychiatric involvement in adult patients with mitochondrial disease. Neurol Sci 2013; 34: 71-4
35. McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol 2010; 9: 829-40
36. Meier DS, Weiner HL, Guttmann CR. Time-series modeling of multiple sclerosis disease activity: A promising window on disease progression and repair potential? Neurotherapeutics 2007; 4: 485-98
37. Mita S, Schmidt B, Schon EA, DiMauro S, Bonilla E. Detection of ?deleted? mitochondrial genomes in cytochrome-c oxidase-deficient muscle fibers of a patient with Kearns-Sayre syndrome. Proc Natl Acad Sci USA 1989; 86: 9509-13
38. Moraes CT, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda AF, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearne-Sayre syndrome. N Engl J Med 1989; 320: 1293-9
39. Moser EB. Repeated measures modeling with PROC MIXED. Proceedings of the 29th SAS Users Group International Conference, 2004
40. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee CS, et al. Longitudinal progression of sporadic Parkinson?s disease: A multi-Tracer positron emission tomography study. Brain 2009; 132: 2970-9
41. Old SL, Johnson MA. Methods of microphotometric assay of succinate dehydrogenase and cytochrome c oxidase activities for use on human skeletal muscle. Histochem J 1989; 21: 545-55
42. Oldfors A, Larsson NG, Holme E, Tulinius M, Kadenbach B, Droste M. Mitochondrial DNA deletions and cytochrome c oxidase deficiency in muscle fibers. Journal of the Neurological Sciences 1992; 110: 169-177
43. Orsucci D, Calsolaro V, Siciliano G, Mancuso M. Quality of life in adult patients with mitochondrial myopathy. Neuroepidemiology 2012; 38: 194-5
44. Pearson HA, Lobel JS, Kocoshis SA, Naiman JL, Windmiller J, Lammi AT, Hoffman R, Marsh JC. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr 1979; 95: 976-984
45. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. Mitochondrial threshold effects. Biochem J 2003; 370: 751-62
46. Rotig A, Bourgeron T, Chretien D, Rustin P, Munnich A. Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Hum Mol Genet 1995; 4: 1327-30
47. Sadikovic B, Wang J, El-Hattab A, Landsverk M, Douglas G, Brundage EK. Sequence homology at the breakpoint and clinical phenotype of mitochondrial DNA deletion syndromes. PLoS One 2010; 5: E15687
48. Schaefer AM, Phoenix C, Elson JL, McFarland R, Chinnery PF, Turnbull DM. Mitochondrial disease in adults: A scale to monitor progression and treatment. Neurology 2006; 66: 1932-4
49. Schon EA, Rizzuto R, Moraes CT, Nakase H, Zeviani M, DiMauro S. A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science 1989; 244: 346-9
50. Schon EA, Dimauro S, Hirano M. Human mitochondrial DNA: Roles of inherited and somatic mutations. Nature Reviews Genetics 2012; 13: 878-90
51. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. Journal of Educational and Behavioral Statistics 1998; 23: 323-55
52. Thomas VP. What?s wrong with Bonferroni adjustments. BMJ 1998; 316: 1236-8
53. Tornatore JB, Grant LA. Burden among family caregivers of persons with Alzheimer?s disease in nursing homes. Gerontologist 2002; 42: 497-506
54. Vu TC, Nutt JG, Holford HG. Progression of motor and nonmotor features of Parkinson?s disease and their response to treatment. British Journal of Clinical Pharmacology 2012; 74: 267-83
55. Whittaker RG, Blackwood JK, Alston CL, Blakely EL, Elson JL, McFarland R, et al. Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A4G mtDNA mutation. Neurology 2009; 72: 568-9
56. Yamashita S, Nishino I, Nonaka I, Goto Y. Genotype and phenotype analyses in 136 patients with single large-scale mitochondrial DNA deletions. Journal of Human Genetics 2008; 53: 598-606
57. Yatsuga S, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T, et al. MELAS: A nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 2012; 1820: 619-24
58. Zeviani M, Moraes CT, DiMauro S, Nakase H, Bonilla E, Schon EA, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988; 38: 1339-46